COMPOUND DEEP DIVES
Melanotan-2 (MT-II) is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (α-MSH) that has attracted considerable attention in the preclinical literature for its high-affinity interactions with the melanocortin receptor family. Developed originally to investigate photoprotective mechanisms in skin biology, Melanotan-2 research has expanded into neuroendocrine pharmacology, neuroprotection, and receptor-subtype selectivity studies. This article reviews the structural biology of MT-II, the melanocortin receptor system, and representative findings from animal and cell-based models — all within a strictly scientific and laboratory research context.
MT-II is a cyclic lactam heptapeptide with the sequence Ac-Nle-c[Asp-His-d-Phe-Arg-Trp-Lys]-NH₂. The introduction of d-Phe at position 7 and the lactam bridge between Asp and Lys confer conformational rigidity that dramatically enhances receptor binding affinity and metabolic stability relative to the native α-MSH tridecapeptide (Al-Obeidi FA et al., J Med Chem, 1989). This rigidity locks the pharmacophoric His-Phe-Arg-Trp core into a bioactive conformation, which accounts for MT-II’s nanomolar potency at multiple melanocortin receptor subtypes.
Radiolabelled binding assays conducted in transfected HEK-293 cell lines have demonstrated that MT-II binds MC1R, MC3R, MC4R, and MC5R with Ki values in the low nanomolar range, making it a broadly useful non-selective melanocortin agonist tool compound in preclinical receptor pharmacology (Hadley ME, Ann NY Acad Sci, 2005). Its selectivity profile is therefore distinct from naturally occurring peptides such as α-MSH (preferring MC1R) or γ-MSH (preferring MC3R), rendering MT-II a valuable probe for dissecting receptor-subtype contributions in complex biological systems.
For researchers interested in related peptide backbone research, preclinical studies on BPC-157 offer a complementary perspective on cyclic and linear peptide pharmacology in tissue-repair models.
The melanocortin system comprises five G-protein-coupled receptors (MC1R–MC5R), each coupled primarily to Gαs and downstream cAMP signalling. Their distinct tissue distributions create a roadmap for understanding which receptor mediates which physiological effect in preclinical models. The table below summarises key characteristics relevant to laboratory research contexts.
| Receptor | Primary Tissue Expression | Key Endogenous Ligand | Preclinical Research Applications |
|---|---|---|---|
| MC1R | Melanocytes, keratinocytes, immune cells | α-MSH | Eumelanin synthesis, UV photoprotection models, skin pigmentation studies |
| MC2R | Adrenal cortex | ACTH (exclusive) | Adrenocortical steroidogenesis; not activated by MT-II |
| MC3R | Hypothalamus, limbic system, gut | α-MSH, γ-MSH | Energy homeostasis circuits, anti-inflammatory signalling in rodent models |
| MC4R | CNS (widespread), brainstem | α-MSH | Hypothalamic feeding behaviour research, autonomic pathway pharmacology |
| MC5R | Exocrine glands, skeletal muscle, skin | α-MSH | Sebaceous gland regulation, immune modulation in rodent models |
The best-characterised preclinical activity of Melanotan-2 research involves MC1R-mediated eumelanin production. MC1R is a Gαs-coupled receptor expressed on melanocytes; its activation elevates intracellular cAMP, which in turn upregulates microphthalmia-associated transcription factor (MITF) and downstream enzymes of the melanogenic cascade, principally tyrosinase. In C57BL/6 and agouti-signal protein (ASP) knock-in mouse models, systemic administration of MT-II has been shown to shift the pheomelanin:eumelanin ratio markedly toward eumelanin production, resulting in measurable darkening of fur pigmentation (Hadley ME, Ann NY Acad Sci, 2005).
From a photoprotection research perspective, eumelanin’s broader UV absorption spectrum compared with pheomelanin has prompted investigators to use MT-II-treated rodent models to study whether pharmacological upregulation of MC1R activity reduces UV-induced DNA damage markers such as cyclobutane pyrimidine dimers (CPDs). Early reports in hairless mouse models documented reductions in epidermal CPD burden following MT-II treatment preceding UV exposure, suggesting that MC1R agonism may be a tractable target for photoprotection pharmacology — a finding with implications for dermatology research rather than any clinical recommendation.
MC4R is expressed throughout the central nervous system, with particularly dense representation in the paraventricular nucleus of the hypothalamus, brainstem nuclei, and limbic structures. Because MT-II binds MC4R with high affinity, it has been extensively employed in rodent and non-human primate models to probe the pharmacological consequences of central melanocortin system activation. Investigations in MC4R knock-out mice have been especially informative: the hyperphagic, obese phenotype of these animals, and its partial reversal by viral re-expression of MC4R in specific hypothalamic nuclei, has helped map discrete neural circuits regulating energy balance (Al-Obeidi FA et al., J Med Chem, 1989).
Beyond metabolic circuits, neuroprotective melanocortin signalling represents an active area of preclinical inquiry. In ischaemia-reperfusion models, central MC4R activation has been associated with reductions in pro-inflammatory cytokine expression and neuronal apoptosis markers in rodent brain tissue. Researchers have used MT-II as a pharmacological tool to confirm that these neuroprotective signals are melanocortin-receptor-dependent rather than off-target effects of the peptide scaffold. These findings contribute to a broader literature on neuropeptide-mediated cytoprotection explored across multiple peptide classes — a theme also examined in introductory reviews of research peptide pharmacology.
A distinct but closely related area of melanocortin pharmacology concerns the potential of Melanotan-2 to reduce UV-induced genomic damage through MC1R-mediated upregulation of the melanogenic cascade. Solar ultraviolet radiation — principally UVB (280–315 nm) — induces the formation of cyclobutane pyrimidine dimers (CPDs) and 6-4 photoproducts in epidermal DNA. If left unrepaired, these lesions drive mutagenic transitions associated with actinic pathology. Eumelanin acts as a broadband UV absorber and free-radical quencher within the melanosome, physically intercepting photons before they reach nuclear DNA. Because MC1R agonism promotes the enzymatic switch from pheomelanin to eumelanin synthesis via the MITF–tyrosinase axis, investigators have hypothesised that pharmacological activation of MC1R could enhance intrinsic photoprotective capacity in melanocyte models.
Cell-based studies using primary human melanocyte cultures and reconstituted skin equivalents have demonstrated that Melanotan-2 treatment increases melanin density and shifts pigment composition toward eumelanin, as quantified by electron spin resonance spectroscopy and HPLC-based melanin fractionation. In hairless mouse UV exposure studies, animals pre-treated with MT-II exhibited statistically significant reductions in epidermal CPD burden — measured by immunohistochemistry with CPD-specific antibodies — compared with vehicle-treated controls receiving equivalent UV doses. These observations implicate the MC1R-cAMP-MITF pathway as a mechanistically distinct photoprotective route that operates at the cellular level rather than on the skin surface.
This mechanistic distinction is relevant when comparing MC1R-mediated photoprotection with conventional physical and chemical sunscreen technologies. Broad-spectrum topical sunscreens attenuate UV flux by absorbing or scattering photons external to the stratum corneum, providing barrier-level protection that is dose-dependent and wash-off susceptible. By contrast, MC1R-mediated eumelanogenesis augments the intrinsic optical density of the melanocyte, increasing the biological pathlength a photon must traverse before reaching nuclear DNA. The two mechanisms therefore operate at fundamentally different biological depths, and their potential complementarity represents an active area of inquiry in photobiology and dermatological pharmacology research. All findings cited here derive from controlled preclinical and cell-model experimental contexts only.
In preclinical and laboratory settings, Melanotan-2 (MT-II) is used as a non-selective melanocortin receptor agonist tool compound. It enables researchers to study MC1R-mediated pigmentation pathways, MC4R-mediated hypothalamic circuit pharmacology, and broader melanocortin system contributions to neuroendocrine and inflammatory regulation — all within in vitro cell systems or controlled animal models.
MT-II binds MC1R with nanomolar affinity through its His-d-Phe-Arg-Trp pharmacophore. Upon receptor engagement, Gαs activation raises intracellular cAMP, activating protein kinase A and subsequently MITF, which transcriptionally upregulates tyrosinase and related enzymes responsible for converting tyrosine to eumelanin within melanocyte cell bodies. This mechanism has been confirmed using MC1R-specific antagonists and receptor knock-out mouse lines.
Alpha-MSH is a linear tridecapeptide with modest metabolic stability and moderate receptor selectivity, displaying preference for MC1R. MT-II, by contrast, is a conformationally constrained cyclic heptapeptide that binds MC1R, MC3R, MC4R, and MC5R with similarly high affinity. This broad receptor engagement makes MT-II a useful non-selective probe for identifying which receptor subtypes mediate observed effects in complex tissue preparations, while its metabolic resistance to enzymatic degradation extends its utility in longer-duration in vivo protocols.
Hairless mouse strains (e.g., Skh-1) and pigmented C57BL/6 mice are the most commonly reported animal models in MT-II photoprotection research. Investigators measure outcomes including UV-induced erythema scoring, epidermal cyclobutane pyrimidine dimer quantification by immunohistochemistry, and melanin content by Fontana-Masson staining. These endpoints provide quantitative indices of potential MC1R-mediated photoprotective mechanisms at the tissue level.
Preclinical evidence suggests that melanocortin receptor activation, including via MT-II in rodent ischaemia models, is associated with reductions in inflammatory cytokine expression (IL-1β, TNF-α) and neuronal apoptosis markers in brain tissue. MT-II is used as a pharmacological tool in these models to confirm melanocortin-receptor-dependent mechanisms, contributing to a body of literature on neuropeptide-mediated CNS cytoprotection. All such findings are strictly from controlled animal model contexts.
MT-II intended for laboratory and scientific research purposes is available from specialist peptide suppliers. Researchers should confirm certificate of analysis (CoA) documentation, including HPLC purity data and mass spectrometry confirmation, before use in experimental protocols. MT-II is supplied exclusively for in vitro and animal model research under appropriate institutional oversight.
View Melanotan-2 research compound →
Each compound available on biohacker.team is verified by our specialist research team through independent third-party HPLC authentication, with batch-level certificates of analysis published openly. Our experts cross-reference purity data against established preclinical literature before each batch is listed.
This article is for informational and educational purposes only. All compounds discussed are intended strictly for laboratory and scientific research use. Not for human consumption. Not for sale to the public.